Adults with Poorly Controlled Asthma

Purpose of this Study

We are doing this study to find out if L-citrulline (the study drug) will help improve asthma symptoms when taken daily. This study is important because managing symptoms of asthma can improve quality of life and long-term health.

Who Can Participate?

Eligibility

Adults ages 18-65 who:
- Are not pregnant
- Have been diagnosed with asthma by a healthcare provide at least 6 months ago
- Are currently taking an ICS or ICS/LABA medication such as Symbicort, Pulmicort, Advair, or QVar
- Have a BMI greater than 30

For more information about who can join this study, please contact the study team at DukeAirwayResearch@duke.edu or 919-479-0861.

Age Range

18-65

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
Yes

What is Involved?

If you choose to join this study, you will:
- Answer questionnaires
- Have your lung function tested
- Give blood and urine samples
- Undergo methacholine challenges (breathing tests to test your airways)

Study Dosing Period: During this period of the study, you will:
- Be randomized (like flipping a coin) to 1 of 2 groups
-- One group will take the study drug (L-citrulline) by mixing a powder into water once a day for 7 weeks
-- The other group will take a placebo (sugar powder) by mixing the powder into water once a day for 7 weeks
- Complete an asthma questionnaire 4 weeks after your first dose
- Complete breathing tests before and after taking the first and last dose of the study drug/placebo

You also have the option to participate in a bronchoscopy where cells from your lungs will be collected to study how well L-citrulline works.

Locations

Other

Visit Timing

Weekdays

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

SANDIA: Supplementing L-citrulline to overweight late Asthma oNset phenotypes to increase airway L-arginine/ADMA ratio and Improve Asthma control

Principal Investigator

Loretta
Que

Protocol Number

PRO00104357

NCT ID

NCT03885245

Phase

Pilot

Enrollment Status

OPEN TO ACCRUAL